Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation

Fetal Diagnosis and Therapy

Volumn 36, Issue 1, 2014, Pages 9-17

  Garcia Tizon Larroca, Santiago ^a   Tayyar, Ahmet ^a   Poon, Leona C ^a   Wright, David ^b   Nicolaides, Kypros H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

Mean arterial pressure; Placental growth factor; Preeclampsia; Pyramid of antenatal care; Soluble fms like tyrosine kinase 1; Third trimester screening; Uterine artery Doppler

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; PLACENTA PROTEIN; BIOCHEMICAL MARKER;

ADULT; ARTICLE; BIOCHEMISTRY; BIOPHYSICS; FALSE POSITIVE RESULT; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL TIME; THIRD TRIMESTER PREGNANCY; UTERINE ARTERY PULSATILITY INDEX; BIOLOGICAL MODEL; BLOOD; PRE-ECLAMPSIA; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES; RISK FACTOR; STATISTICAL MODEL; CONTROLLED STUDY; DELIVERY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GESTATION PERIOD; MEASUREMENT; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SCREENING;

ADULT; BIOLOGICAL MARKERS; FEMALE; GESTATIONAL AGE; HUMANS; LINEAR MODELS; MODELS, BIOLOGICAL; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, THIRD; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84904389353     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000362518     Document Type: Article

References (40)

1. World Health Organization: Make Every Mother and Child Count. World Health Report, 2005. Geneva, WHO, 2005
2. Confidential Enquiry into Maternal and Child Health (CEMACH) Perinatal Mortality 2006: England, Wales and Northern Ireland. London, CEMACH, 2008
3. Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-137
4. Khong TY, De Wolf F, Robertson WB, Brosens I: Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 1049-1059
5. Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, van Assche A: Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991; 98: 648-655
6. Bdolah Y, Sukhatme VP, Karumanchi SA: Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. Semin Nephrol 2004; 24: 548-556
7. Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196
8. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH: Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013; 33: 8-15
9. Poon LC, Kametas NA, Maiz N, Akolekar R, Nicolaides KH: First-Trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53: 812-818
10. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, Forest JC, Giguere Y: Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: A meta-Analysis. Obstet Gynecol 2010; 116: 402-414
11. Roberge S, Villa P, Nicolaides K, Giguere Y, Vainio M, Bakthi A, Ebrashy A, Bujold E: Early administration of low dose aspirin for the prevention of preterm and term pre-eclampsia: A systematic review and meta-Analysis. Fetal Diagn Ther 2012; 31: 141-146
12. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, van Den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW, Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A, Papatsonis DN, van Der Post JA, Roumen FJ, Scheepers HC, Willekes C, Mol BW, van Pampus MG; HYPITAT Study Group: Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): A multicentre, open-label randomised controlled trial. Lancet 2009; 374: 979-988
13. Wright D, Akolekar R, Syngelaki A, Poon LC, Nicolaides KH: A competing risks model in early screening for preeclampsia. Fetal Diagn Ther 2012; 32: 171-178
14. Tayyar A, Garcia-Tizon Larroca S, Poon LC, Wright D, Nicolaides KH: Competing risks model in screening for preeclampsia by mean arterial pressure and uterine artery pulsatility index at 30-33 weeks' gestation. Fetal Diagn Ther 2014, in press
15. Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH: Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation. Fetal Diagn Ther 2014, in press
16. Robinson HP, Fleming JE: A critical evaluation of sonar crown-rump length measurements. Br J Obstet Gynaecol 1975; 82: 702-710
17. Reinders A, Cuckson AC, Lee JT, Shennan AH: An accurate automated blood pressure device for use in pregnancy and pre-eclampsia: The Microlife 3BTO-A. BJOG 2005; 112: 915-920
18. Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH: Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation. Fetal Diagn Ther 2012; 31: 42-48
19. Albaiges G, Missfelder-Lobos H, Lees C, Parra M, Nicolaides KH: One-stage screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23 weeks' gestation. Obstet Gynecol 2000; 96: 559-564
20. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX-XIV
21. Poon LCY, Volpe N, Muto B, Syngelaki A, Nicolaides KH: Birthweight with gestation and maternal characteristics in live births and stillbirths. Fetal Diagn Ther 2012; 32: 156-165
22. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data, ed 2. New York, Wiley, 2002
23. R Core Team: R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2013. URL http://www.R-project. org/.
24. Torry DS, Mukherjea D, Arroyo J, Torry RJ: Expression and function of placenta growth factor: Implications for abnormal placentation. J Soc Gynecol Investig 2003; 10: 178-188
25. Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F, Foidart JM: Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 2008; 23: 1407-1415
26. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase-1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658
27. Roberts JM, Redman CW: Pre-eclampsia: More than pregnancy-induced hypertension. Lancet 1993; 341: 1447-1451
28. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA: Pathophysiology of hypertension During preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001; 38: 718-722
29. Van Asselt K, Gudmundsson S, Lindqvist P, Marsal K: Uterine and umbilical artery velocimetry in pre-eclampsia. Acta Obstet Gynecol Scand 1998; 77: 614-619
30. Hernandez-Andrade E, Brodszki J, Lingman G, Gudmundsson S, Molin J, Marsal K: Uterine artery score and perinatal outcome. Ultrasound Obstet Gynecol 2002; 19: 438-442
31. Frusca T, Soregaroli M, Platto C, Enterri L, Lojacono A, Valcamonico A: Uterine artery velocimetry in patients with gestational hypertension. Obstet Gynecol 2003; 102: 136-140
32. Li H, Gudnason H, Olofsson P, Dubiel M, Gudmundsson S: Increased uterine artery vascular impedance is related to adverse outcome of pregnancy but is present in only onethird of late third-Trimester pre-eclamptic women. Ultrasound Obstet Gynecol 2005; 25: 459-463
33. Ghi T, Youssef A, Piva M, Contro E, Segata M, Guasina F, Gabrielli S, Rizzo N, Pelusi G, Pilu G: The prognostic role of uterine artery Doppler studies in patients with late-onset preeclampsia. Am J Obstet Gynecol 2009; 201: 36. e1-5
34. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, Calda P, Holzgreve W, Galindo A, Engels T, Denk B, Stepan H: The sFlt-1/PlGF ratio in Different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206: 58.e1-8
35. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA: Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-919
36. Chaiworapongsa T, Romero R, Savasan ZA, Kusanovic JP, Ogge G, Soto E, Dong Z, Tarca A, Gaurav B, Hassan SS: Maternal plasma concentrations of angiogenic/anti-Angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med 2011; 24: 1187-1207
37. Sibiude J, Guibourdenche J, Dionne MD, Le Ray C, Anselem O, Serreau R, Goffinet F, Tsatsaris V: Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012; 7:e50208
38. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, Waugh J, Anumba D, Kenny LC, Redman CW, Shennan AH: Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: A prospective multicenter study. Circulation 2013; 128: 2121-2131
39. Ohkuchi A, Hirashima C, Takahashi K, Suzuki H, Matsubara S, Suzuki M: Onset threshold of the plasma levels of soluble fms-like tyrosine kinase-1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation. Hypertens Res 2013; 36: 1073-1080
40. Ministry of Health Report: 1929 Memorandum on Antenatal Clinics: Their Conduct and Scope. London, HMSO, 1930.